$1.25
+0.01 (+0.81%)
Open$1.28
Previous Close$1.24
Day High$1.30
Day Low$1.16
52W High$40.94
52W Low$23.29
Volume—
Avg Volume577.8K
Market Cap13.27M
P/E Ratio37.29
EPS$0.73
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,616.8% upside
Current
$1.25
$1.25
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.71M | 1.55M | 1.32M |
| Net Income | 376.4K | 361.3K | 275.7K |
| Profit Margin | 22.0% | 23.4% | 20.8% |
| EBITDA | 487.6K | 534.5K | 383.7K |
| Free Cash Flow | 289.2K | 193.8K | 220.9K |
| Rev Growth | +21.2% | +15.5% | +14.1% |
| Debt/Equity | 1.40 | 1.22 | 1.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |